Loading...
XNASNTLA
Market cap1.24bUSD
Jan 03, Last price  
12.13USD
1D
-0.74%
1Q
-32.57%
Jan 2017
-7.48%
IPO
-49.46%
Name

Intellia Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:NTLA chart
P/E
—
P/S
34.06
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
15.56%
Rev. gr., 5y
3.57%
Revenues
36m
-30.40%
06,044,00016,479,00026,117,00030,434,00043,103,00057,994,00033,053,00052,121,00036,275,000
Net income
-481m
L-1.84%
-14,308,500-12,397,000-31,634,000-67,543,000-85,343,000-92,698,000-125,568,000-259,718,000-490,208,000-481,192,000
CFO
-394m
L+18.24%
-3,483,000-1,763,00036,109,000-65,276,000-61,257,000-103,240,000-49,912,000-225,030,000-333,287,000-394,086,000
Earnings
Feb 20, 2025

Profile

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
URL
https://www.intelliatx.com/
IPO date
May 06, 2016
Employees
598
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
36,275
-30.40%
52,121
57.69%
Cost of revenue
560,542
517,857
Unusual Expense (Income)
NOPBT
(524,267)
(465,736)
NOPBT Margin
Operating Taxes
16,022
Tax Rate
NOPAT
(524,267)
(481,758)
Net income
(481,192)
-1.84%
(490,208)
88.75%
Dividends
Dividend yield
Proceeds from repurchase of equity
119,795
565,789
BB yield
-4.43%
-21.07%
Debt
Debt current
37,198
16,685
Long-term debt
212,093
244,721
Deferred revenue
38,853
19,932
Other long-term liabilities
24,026
Net debt
(817,444)
(1,142,874)
Cash flow
Cash from operating activities
(394,086)
(333,287)
CAPEX
(13,985)
(58,390)
Cash from investing activities
(31,347)
160,309
Cash from financing activities
130,323
582,955
FCF
(519,502)
(542,644)
Balance
Cash
912,223
1,261,960
Long term investments
154,512
142,320
Excess cash
1,064,921
1,401,674
Stockholders' equity
(1,660,628)
(1,184,639)
Invested Capital
2,883,595
2,594,884
ROIC
ROCE
EV
Common stock shares outstanding
88,770
76,972
Price
30.49
-12.61%
34.89
-70.49%
Market cap
2,706,597
0.78%
2,685,553
-67.96%
EV
1,889,153
1,542,679
EBITDA
(515,291)
(458,164)
EV/EBITDA
Interest
8,542
Interest/NOPBT